COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB® at NATA24 Annual Symposium
Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB at NATA24 Annual Symposium in Bologna, Italy. Prof. Dr. med. Patrick Meybohm to present safety and efficacy data -
-
-
-
COMMUNIQUÉ DE PRESSE
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
Bausch Health, Canada Inc. announces availability of ARAZLO lotion for acne treatment through BC PharmaCare. ARAZLO offers unique formulation technology to enhance patient tolerability -
COMMUNIQUÉ DE PRESSE
Le traitement de l’acné vulgaire par PrARAZLO(MC) (lotion de tazarotène, 0,045 %) est maintenant accessible aux patients couverts par PharmaCare, le régime d’assurance-médicaments public de la Colombie-Britannique
Bausch Health annonce l'accessibilité de la lotion ARAZLO aux patients de la Colombie-Britannique couverts par PharmaCare pour traiter l'acné. La technologie PRISMATREXMC favorise la tolérabilité du traitement -
COMMUNIQUÉ DE PRESSE
ParetoHealth Welcomes Industry Veteran CFO and Announces Appointment of First Chief Product Officer to Support Continued Growth and Scale
ParetoHealth announces strategic expansion of executive team with new CFO and Chief Product Officer to drive growth in redefining employee health benefits -
-
